Now, in a new study using laboratory - grown cells and mice, Johns Hopkins scientists report that a method they used to track metabolic pathways heavily
favored by cancer cells provides scientific evidence for combining anti-cancer drugs, including one in a nanoparticle format developed at Johns Hopkins, that specifically target those pathways.
Not exact matches
The research suggests that reducing production of the protein, called myoferlin, affects
cancer cells in two primary ways:
by changing the activation of many genes involved in metastasis in
favor of normal
cell behavior, and
by altering mechanical properties of
cancer cells — including their shape and ability to invade — so they are more likely to remain nested together rather than breaking away to travel to other tissues.
It has been postulated that hypoxia contributes directly to the development of more aggressive
cancers by exerting selective pressure on the tumor
cell population to
favor cells that can survive decreased O2 and nutrients [18 — 20].
Other times, the
cancer cells» growth is encouraged
by these conditions that they
favor, such as chronic inflammation, greater levels of insulin, poorly oxygenated blood, too much cortisol (a natural stress hormone), and excessive estrogen or testosterone.»